Jason B. Litten
Technik-/Wissenschafts-/F&E-Leiter bei CHIMERIC THERAPEUTICS LIMITED
Profil
Jason B.
Litten is currently the Chief Medical Officer at Chimeric Therapeutics Ltd.
(Australia) and also holds the position of Chief Medical Officer at Optera Therapeutics Corp.
He previously worked as Vice President-Clinical Development at Clovis Oncology, Inc. and Juno Therapeutics, Inc. From 2019 to 2022, he served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. Litten holds a doctorate degree from Emory University and an undergraduate degree from Cornell University.
Aktive Positionen von Jason B. Litten
Unternehmen | Position | Beginn |
---|---|---|
CHIMERIC THERAPEUTICS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 25.07.2022 |
Optera Therapeutics Corp. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Jason B. Litten
Unternehmen | Position | Ende |
---|---|---|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 06.06.2022 |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - |
JUNO THERAPEUTICS INC | Corporate Officer/Principal | - |
Ausbildung von Jason B. Litten
Emory University | Doctorate Degree |
Cornell University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CHIMERIC THERAPEUTICS LIMITED | Health Technology |
Private Unternehmen | 4 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
Optera Therapeutics Corp. |